A Polypill for Acute Coronary Syndrome
Sponsor: University of Texas Southwestern Medical Center • ClinicalTrials.gov ID: NCT07032389
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
The current study aims to investigate whether combining the standard medications prescribed after acute coronary syndrome (ACS)-aspirin, P2Y12 inhibitors, and statins-into a single polypill can improve outcomes following an ACS event. Although these therapies are effective, gaps in adherence and uptake significantly contribute to risk or adverse events in the post-ACS period. This study is designed as a pragmatic, multi-center, randomized trial to assess the feasibility and effectiveness of a polypill-based strategy for treatment of ACS.
Interventions
-
Polypill
(Combination product)
The polypill is an inert capsule designed to combine multiple individual medications into a convenient, once-daily pill. In this case it will include DAPT and a statin.
Eligibility criteria
Conditions
Locations
- Baylor Scott & White, The Heart Hospital, Plano (THH, Plano) — Dallas, Texas, United States
- University of Texas Southwestern Medical Center — Dallas, Texas, United States
- Parkland Health & Hospital System (PHHS) — Dallas, Texas, United States
- Baylor University Medical Center — Dallas, Texas, United States
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record